Types Of Hepatitis And Liver Transplantation

Overview Of Hepatitis

Hepatitis means inflammation of the liver. It can be caused by viruses, immune-related conditions, toxins, alcohol, or metabolic diseases. Viral hepatitis remains a major global cause of cirrhosis and liver cancer. Acute forms often resolve, but chronic infections lead to fibrosis, cirrhosis, and end-stage liver disease requiring transplant in advanced cases. Global burden: 354 million chronic HBV/HCV carriers, 1.1 million deaths annually.

• Hepatitis A & E – usually acute, fecal-oral transmission
• Hepatitis B – blood and body fluid transmission; acute or chronic
• Hepatitis C – bloodborne; often chronic and silent
• Hepatitis D – requires hepatitis B
• Autoimmune and other forms – immune-mediated or metabolic

Acute Hepatitis A & E

Hepatitis A and E typically cause acute, short-lived infections and rarely lead to chronic liver disease in immunocompetent adults. Spread through contaminated food or water, symptoms include fatigue, jaundice, nausea, and abdominal discomfort. Most recover fully with supportive care; severe acute liver failure is uncommon but can occur in older adults or during pregnancy. Vaccination prevents HAV; HEV vaccine available in some regions.

• Incubation: 15–50 days (HAV), 2–8 weeks (HEV)
• Fulminant failure risk: <1% in healthy, up to 20% in pregnant women
• No specific antivirals; transplant rare but lifesaving in fulminant cases

Vaccination for chronic liver patients is crucial to avoid decompensation.^[2]

Chronic Hepatitis B

Chronic hepatitis B (HBV) remains a major cause of cirrhosis and hepatocellular carcinoma worldwide, affecting 296 million people. Transmitted by blood, sexual contact, or perinatally, it can be inactive, immune-active, or reactivated with immunosuppression. Long-term infection increases risk of cirrhosis (15–40%) and liver cancer (2–5% annually). Potent antivirals like entecavir/tenofovir suppress replication in 90–95%, delaying progression and reducing transplant need.

• Phases: Immune-tolerant, immune-active, inactive carrier
• HCC surveillance: Ultrasound/AFP every 6 months
• Transplant: For decompensated cirrhosis or HCC; prophylaxis prevents recurrence

Global elimination target: 90% reduction in deaths by 2030.^[3]

Chronic Hepatitis C

Chronic hepatitis C (HCV) used to be one of the most common reasons for liver transplantation, affecting 58 million globally. Bloodborne transmission (historically transfusions/injection drugs), often silent for years before cirrhosis (20–30%). Direct-acting antivirals (DAAs) achieve >95% cure rates in 8–12 weeks, reducing waitlist mortality by 50%. Even post-cure, advanced fibrosis patients remain at HCC risk (1–3% yearly).

• Genotypes: 1–6; pan-genotypic DAAs simplify treatment
• Extrahepatic: Cryoglobulinemia, lymphoma
• Transplant: Reinfection 25–30%; DAAs cure 95% post-LT

Elimination goal: Diagnose 90%, treat 80% by 2030.^[1]

Other Hepatitis Types And Causes

Several additional forms are important in transplant candidates. Hepatitis D (HDV) requires HBV co-infection, causing aggressive cirrhosis in 70–80%. Autoimmune hepatitis (AIH) attacks liver cells, treated with steroids/azathioprine; 20% progress to cirrhosis needing transplant. Drug-induced (e.g., acetaminophen) causes acute failure; metabolic (NASH) drives 25% U.S. transplants. Alcoholic hepatitis fulminant cases may qualify for early LT.

• HDV: Ribavirin/bulevirtide emerging therapies
• AIH: Liver biopsy for diagnosis; overlap with PBC/PSC
• Transplant: Recurrence risk low except AIH (20–30%)

Multidisciplinary management key to delaying progression.^[3]

Hepatitis And Liver Transplant Candidacy

Patients with hepatitis qualify for transplant if decompensated (ascites, encephalopathy, varices) or HCC within Milan criteria. Viral hepatitis accounts for 40% global LTs; pre-LT viral suppression improves outcomes. HBV/HCV cure pre-LT delists 20–30%; HDV/AIH require immunosuppression adjustment. Contraindications: Uncontrolled viremia, active drug use without treatment.

• MELD prioritization for decompensation
• HCC exception points
• Psychosocial evaluation mandatory

1-year survival >90% with modern care.^[3]

After Transplant: Recurrence & Prevention

Post-LT monitoring prevents recurrence: HBV prophylaxis (HBIG + antivirals) in 95%; HCV DAAs cure reinfection 95%. Vaccinate against HAV/HEV; AIH recurs 20–30% but steroid-responsive. HCC surveillance continues. Lifestyle: Abstinence from alcohol, HBV vaccination for contacts. Long-term: 80% 5-year survival; annual biopsies for high-risk.

• HBV: Lifelong entecavir
• HCV: Treat within 3 months post-LT
• Follow-up: q3–6 months labs/imaging